France· FR:68822785
RYSTIGGO 140 mg/mL, solution injectable
A medicinal product containing rozanolixizumab, registered in France by UCB PHARMA BELGIQUE, on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- ROZANOLIXIZUMAB
- Manufacturer
- UCB PHARMA BELGIQUE
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 3
3 priced- cip1334009302847421 flacon en verre de 2 mLEUR 7.32
- cip1334009303007631 flacon en verre de 3 mLEUR 10.91
- cip1334009303007701 flacon en verre de 4 mLEUR 14.51
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Rozanolixizumab in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesRYSTIGGOUCB, Inc.
- IrelandRystiggo 140 mg/ml solution for injectionUCB Pharma S.A.
- NetherlandsRystiggo 140 mg/ml oplossing voor injectieUCB Pharma S.A.
- BelgiumRystiggo 140 mg/mlUCB Pharma
- CzechiaRYSTIGGOUCB Pharma SA, Brusel
- United KingdomRystiggo 280mg/2ml solution for injection vialsUCB Pharma Ltd
- Japanロザノリキシズマブ（遺伝子組換え）ユーシービージャパン
- SwitzerlandRystiggo 280 mg/2 ml, solution injectableUCB-Pharma SA
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Rystiggo
- Liechtenstein · Rystiggo
- Norway · Rystiggo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/04c9219f-6a85-47ba-b03b-b0ec9060c94a GET /v1/drugs/04c9219f-6a85-47ba-b03b-b0ec9060c94a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "68822785",
"date_amm": "2024-01-05",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/23/1780",
"substance": "ROZANOLIXIZUMAB",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution injectable",
"voies_administration": "sous-cutanée",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Oui"
}See everything about rozanolixizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.